DOCSLIB.ORG

125509 Obiltoxaximab Statistical PREA

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
125509 Obiltoxaximab Statistical PREA U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Office of Translational Sciences Office of Biostatistics S TA TISTICAL R EVIEW AND E VA L U A T I O N ANIMAL EFFICACY STUDIES NDA/BLA #: BLA 125509 Drug Name: Anthim®(obiltoxaximab) 16 mg/kg IV Indication(s): Treatment and Prophylaxis of Inhalational Anthrax due to Bacillus anthracis Applicant: Elusys Therapeutics, Inc. Date(s): Submission date: 3/20/2015. PDUFA due date: 3/18/2016 Review Priority: Standard Biometrics Division: Division of Biometrics IV Statistical Reviewer: Xianbin Li, PhD Concurring Reviewers: Karen Higgins, ScD Daphne Lin, PhD Medical Division: Division of Anti-Infective Products (DAIP) Clinical Team: Elizabeth O'Shaughnessy, MD, Medical Reviewer John Alexander, MD, Medical Team Leader Sumathi Nambiar, MD, Medical Director Project Manager: Jane Dean, RN MSN Keywords: Animal efficacy studies Reference ID: 3859664 Table of Contents 1 EXECUTIVE SUMMARY .................................................................................................. 11 2 INTRODUCTION................................................................................................................ 12 2.1 OVERVIEW........................................................................................................................ 12 2.2 DATA SOURCES ................................................................................................................ 13 3 STATISTICAL EVALUATION ......................................................................................... 13 3.1 DATA AND ANALYSIS QUALITY........................................................................................ 13 3.2 EVALUATION OF EFFICACY............................................................................................... 14 3.2.1 Introduction............................................................................................................... 14 3.2.2 IV Treatment Studies................................................................................................. 14 3.2.3 Post-exposure Prophylaxis Studies........................................................................... 27 3.2.4 Pre-exposure Prophylaxis Studies ............................................................................ 33 3.2.5 Re-challenge Study.................................................................................................... 35 3.3 EVALUATION OF SAFETY .................................................................................................. 36 4 FINDINGS IN SPEAL/SUBGROUP POPULATIONS .................................................... 38 4.1 GENDER, RACE, AGE, AND GEOGRAPHIC REGION ............................................................ 38 4.2 OTHER SPECIAL/SUBGROUP POPULATIONS....................................................................... 38 5 SUMMARY AND CONCLUSIONS................................................................................... 39 5.1 STATISTICAL ISSUES ......................................................................................................... 39 5.2 COLLECTIVE EVIDENCE .................................................................................................... 39 5.2.1 Meta-analysis of monkey and rabbits monotherapy studies ........................................ 40 5.2.2 Meta-analysis of PEP studies in monkeys and rabbits ............................................. 40 5.2.3 Efficacy of Lonza ETI-204 ........................................................................................ 42 5.2.4 Summary of collective evidence................................................................................ 43 5.3 CONCLUSIONS AND RECOMMENDATIONS ......................................................................... 45 5.4 LABELING RECOMMENDATIONS ....................................................................................... 45 6 APPENDICES ...................................................................................................................... 47 6.1 OVERVIEW ........................................................................................................................... 47 6.2 IV MONKEY TREATMENT STUDIES................................................................................... 47 6.2.1 Summary of IV monkey treatment studies ................................................................. 47 6.2.2 AP201........................................................................................................................ 49 6.2.3 AP204........................................................................................................................ 58 6.2.4 AP203........................................................................................................................ 67 6.2.5 AP202........................................................................................................................ 77 6.2.6 NIAID1056................................................................................................................ 89 6.3 IV RABBIT TREATMENT STUDIES ..................................................................................... 97 6.3.1 Summary of IV rabbit treatment studies ................................................................... 97 6.3.2 AR021........................................................................................................................ 98 6.3.3 AR033...................................................................................................................... 105 6.3.4 NIAID1030.............................................................................................................. 114 2 Reference ID: 3859664 6.3.5 NIAID1045.............................................................................................................. 120 6.4 MONKEY POST-EXPOSURE PROPHYLAXIS STUDIES ........................................................ 127 6.4.1 Summary of monkey post-exposure prophylaxis studies ......................................... 127 6.4.2 AP107...................................................................................................................... 127 6.4.3 AP301...................................................................................................................... 132 6.4.4 AP307...................................................................................................................... 139 6.5 RABBIT POST-EXPOSURE PROPHYLAXIS STUDIES .......................................................... 147 6.5.1 Summary of rabbit post-exposure prophylaxis studies ........................................... 147 6.5.2 AR004...................................................................................................................... 147 6.5.2 AR007...................................................................................................................... 152 6.5.4 AR012...................................................................................................................... 156 6.5.5 AR034 – Phase I...................................................................................................... 161 6.5.6 AR035...................................................................................................................... 172 6.5.7 AR037...................................................................................................................... 178 6.5.8 AR0315.................................................................................................................... 185 6.6 MONKEY PRE-EXPOSURE PROPHYLAXIS STUDY ............................................................ 191 6.6.1 Summary of monkey pre-exposure prophylaxis study............................................. 191 6.6.2 AP305...................................................................................................................... 191 6.7 RABBIT PRE-EXPOSURE PROPHYLAXIS STUDIES ............................................................ 198 6.7.1 Summary of rabbit pre-exposure prophylaxis studies ............................................ 198 6.7.2 AR001...................................................................................................................... 198 6.7.3 AR003...................................................................................................................... 203 6.8 RE-CHALLENGE STUDY (AR034 PHASE II) ..................................................................... 208 6.9 SUMMARY OF ALL REVIEWED MONOTHERAPY STUDIES .................................................. 209 3 Reference ID: 3859664 LIST OF TABLES Table 1: List of all treatment studies included in analysis ............................................................ 15 Table 2: Survival proportions in monotherapy treatment studies in cynomolgus monkeys (mITT population) .................................................................................................................................... 17 Table 3: Survival proportions in monotherapy treatment studies in cynomolgus monkeys (bacteremic population) ................................................................................................................ 19 Table 4. Pearson correlation coefficients between challenge dose, log10 bacteremia, and log10 PA-ELISA prior to treatment, including two-sided p-value and sample size for each correlation coefficient ....................................................................................................................................
Load more

Recommended publications
  • Where Do Novel Drugs of 2016 Fit In?
    FORMULARY JEOPARDY: WHERE DO NOVEL DRUGS OF 2016 FIT IN? Maabo Kludze, PharmD, MBA, CDE, BCPS, Associate Director Elizabeth A. Shlom, PharmD, BCPS, SVP & Director Clinical Pharmacy Program Acurity, Inc. Privileged and Confidential August 15, 2017 Privileged and Confidential Program Objectives By the end of the presentation, the pharmacist or pharmacy technician participant will be able to: ◆ Identify orphan drugs and first-in-class medications approved by the FDA in 2016. ◆ Describe the role of new agents approved for use in oncology patients. ◆ Identify and discuss the role of novel monoclonal antibodies. ◆ Discuss at least two new medications that address public health concerns. Neither Dr. Kludze nor Dr. Shlom have any conflicts of interest in regards to this presentation. Privileged and Confidential 2016 NDA Approvals (NMEs/BLAs) ◆ Nuplazid (primavanserin) P ◆ Adlyxin (lixisenatide) ◆ Ocaliva (obeticholic acid) P, O ◆ Anthim (obitoxaximab) O ◆ Rubraca (rucaparib camsylate) P, O ◆ Axumin (fluciclovive F18) P ◆ Spinraza (nusinersen sodium) P, O ◆ Briviact (brivaracetam) ◆ Taltz (ixekizumab) ◆ Cinqair (reslizumab) ◆ Tecentriq (atezolizumab) P ◆ Defitelio (defibrotide sodium) P, O ◆ Venclexta (venetoclax) P, O ◆ Epclusa (sofosburvir and velpatasvir) P ◆ Xiidra (lifitigrast) P ◆ Eucrisa (crisaborole) ◆ Zepatier (elbasvir and grazoprevir) P ◆ Exondys 51 (eteplirsen) P, O ◆ Zinbyrta (daclizumab) ◆ Lartruvo (olaratumab) P, O ◆ Zinplava (bezlotoxumab) P ◆ NETSTPOT (gallium Ga 68 dotatate) P, O O = Orphan; P = Priority Review; Red = BLA Privileged and Confidential History of FDA Approvals Privileged and Confidential Orphan Drugs ◆FDA Office of Orphan Products Development • Orphan Drug Act (1983) – drugs and biologics . “intended for safe and effective treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 people in the U.S.
    [Show full text]
  • CDER Therapeutic Biologic Products List
    CDER Therapeutic Biologic Products This list is intended to include all the Center for Drug Evaluation and Research (CDER) user fee billable therapeutic biological products and potencies approved under Section 351 of the Public Health Service Act. The Orange Book includes a section entitled "Drug Products with Approval under Section 505 of the Act Administered by CBER." Included on that list are several products that have been transferred to CDER which would be considered billable also. Program fees are assessed for each potency in which the approved (non-revoked, non-suspended) product is manufactured in final dosage form. When evaluating the specific strength or potency of a drug in final dosage form for purposes of assessing program fees for liquid parenteral biological products, CDER intends to take into consideration both the total amount of drug substance in mass or units of activity in a product and the concentration of drug substance (mass or units of activity per unit volume of product). Biologic products considered to have a different strength or potency in a final dosage form will be given separate entries in the Biologics List and assessed separate program fees. An auto-injector that has the same strength or potency as a prefilled syringe or vial will generally be assessed a separate prescription drug program fee. In certain circumstances, products which have been discontinued from marketing but are still licensed are not assessed program fees. Those products are identified on the CDER Discontinued Biologic Product List section. The potency information contained in this list is based on information in our database.
    [Show full text]
  • Studies on Antitoxin Use for Postexposure Prophylaxis (PEP)
    ACIP Anthrax Vaccine Work Group William Bower, MD, FIDSA Epidemiology Team Lead Bacterial Special Pathogens October 23, 2018 National Center for Emerging and Zoonotic Disease Division of High-Consequence Pathogens and Pathology Outline Overview of anthrax antitoxins Studies on antitoxin use for postexposure prophylaxis (PEP) . Anthrax antitoxin for PEP and survival in animal models . Anthrax antitoxin effect on acquired immunity . Anthrax antitoxin use with anthrax vaccine adsorbed (AVA) Work group discussions Guidance on anthrax antitoxin use for PEP 2 Anthrax Pathogenesis 3 Background – Anthrax Antitoxins There are currently three FDA approved anthrax antitoxins RAXIBACUMAB . Initial U.S. Approval: 2012 . Human IgG1λ monoclonal antibody that binds the protective antigen (PA) component of Bacillus anthracis toxin ANTHRASIL (Anthrax Immune Globulin Intravenous (AIGIV)) . Initial U.S. Approval: 2015 . Purified human IgG containing polyclonal antibodies that bind the protective antigen (PA) component of B. anthracis lethal and edema toxins collected from individuals immunized with AVA ANTHIM (obiltoxaximab) . Initial U.S. Approval: 2016 . Chimeric IgG1 kappa monoclonal antibody that binds the PA component of B. anthracis toxin 4 Background – Anthrax Antitoxins Indications Anthrax antitoxins all have an indication for the treatment of adult and pediatric patients with inhalation anthrax due to B. anthracis in combination with appropriate antimicrobials The monoclonal antitoxins, raxibacumab and obiltoxaximab, are also indicated for
    [Show full text]
  • ENTRY WATCH 2016 Published by the Patented Medicine Prices Review Board June 2018 Meds Entry Watch, 2016 Is Available in Electronic Format on the PMPRB Website
    MEDS ENTRY WATCH 2016 Published by the Patented Medicine Prices Review Board June 2018 Meds Entry Watch, 2016 is available in electronic format on the PMPRB website. Une traduction de ce document est également disponible en français sous le titre : Veille des médicaments mis en marché, 2016 Patented Medicine Prices Review Board Standard Life Centre Box L40 333 Laurier Avenue West Suite 1400 Ottawa, ON K1P 1C1 Tel.: 1-877-861-2350 TTY 613-288-9654 Email: [email protected] Web: www.pmprb-cepmb.gc.ca ISSN 2560-6204 Cat. No.: H79-12E-PDF © Her Majesty the Queen in Right of Canada, as represented by the NPDUIS initiative of the Patented Medicine Prices Review Board, 2018 MEDS ENTRY WATCH 2016 About the PMPRB Acknowledgements The Patented Medicine Prices Review Board This report was prepared by the Patented (PMPRB) is a respected public agency that makes Medicine Prices Review Board (PMPRB) a unique and valued contribution to sustainable as part of the National Prescription Drug spending on pharmaceuticals in Canada by: Utilization Information System (NPDUIS). ~ providing stakeholders with price, cost and The PMPRB would like to acknowledge the utilization information to help them make timely contributions of and knowledgeable drug pricing, purchasing and ~ The members of the NPDUIS Advisory reimbursement decisions; and Committee for their expert oversight and ~ acting as an effective check on the patent rights guidance in the preparation of this report. of pharmaceutical manufacturers through the ~ PMPRB NPDUIS staff for their contribution responsible and efficient use of its consumer to the analytical content of the report: protection powers.
    [Show full text]
  • Therapeutic Monoclonal Antibodies for Respiratory Diseases: Current Challenges & Perspectives March 31 - April 1, 2016
    Therapeutic Monoclonal Antibodies for Respiratory Diseases: Current Challenges & Perspectives March 31 - April 1, 2016 Janice M. Reichert, Ph.D. Executive Director, The Antibody Society Editor-in-Chief, mAbs 1 Topics for discussion Overview of the antibody therapeutics clinical pipeline* ‘Other’ disorders, incl. respiratory disorders Antibodies recently approved or in regulatory review Antibodies in clinical studies Prospects for 2016 *Disclaimer: Commercial development; only public domain information known as of Feb 15, 2016 is included. It should be noted that frequent changes to the data occur over time. 2 3 Novel antibodies entering clinic* 120 102 100 81 80 66 54 60 50 40 20 0 2011 2012 2013 2014 2015 Year of first clinical study *Commercial development only Antibodies in Phase 3 studies 60 53 50 39 40 33 29 30 26 25 25 20 Number of mAbs in Phase 3 Phase in mAbs of Number 10 0 2010 2011 2012 2013 2014 2015 2016 Year of article publication Data from ‘Antibodies to watch’ articles published in mAbs. 5 10 11 Number of first approvals for mAbs of mAbs US or EU approvals First 0 1 2 3 4 5 6 7 8 9 the US or EU (antibodysociety.org) or US the in or in review approved of antibodies Table Source: approvals. number of first *Projected 97 98 99 00 01 02 Year of first US EUor approval of first Year 03 04 05 06 07 08 09 10 11 12 13 14 15 10+ ? 6 16* Three approvals in 2016 so far… Obiltoxaximab, targeting PA of B. anthracis exotoxin approved by FDA on March 18 ANTHIM® is indicated in adult and pediatric patients for treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or appropriate.
    [Show full text]
  • 125509Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 125509Orig1s000 OTHER REVIEW(S) REGULATORY PROJECT MANAGER PHYSICIAN’S LABELING RULE (PLR) FORMAT REVIEW OF THE PRESCRIBING INFORMATION Complete for all new NDAs, BLAs, Efficacy Supplements, and PLR Conversion Labeling Supplements Application: BLA 125509 Application Type: New BLA Name of Drug/Dosage Form: Anthim (obiltoxaximab) Injection, for intravenous use Applicant: Elusys Therapeutics Receipt Date: March 20, 2015 Goal Date: March 18, 2016 1. Regulatory History and Applicant’s Main Proposals Elusys Therapeutics, Inc. submitted a new Biologics Licensing Application (BLA) under section 351(a) of the Public Health Service Act and 21CFR Part 601, Subpart H (Approval of a Biologic Product When Human Efficacy Studies are not Ethical or Feasible) Anthim (obiltoxaximab) with the following indications: treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and prophylaxis of inhaltional anthrax when alternative therapies are not available or are not appropriate. 2. Review of the Prescribing Information This review is based on the applicant’s submitted Word format of the prescribing information (PI). The applicant’s proposed PI was reviewed in accordance with the labeling format requirements listed in the “Selected Requirements for Prescribing Information (SRPI)” checklist (see Section 4 of this review). 3. Conclusions/Recommendations No SRPI format deficiencies were identified in the review of this PI. 4. Selected Requirements of Prescribing Information The Selected Requirement of Prescribing Information (SRPI) is a 41-item, drop-down checklist of important format elements of the prescribing information (PI) based on labeling regulations (21 CFR 201.56 and 201.57) and guidances.
    [Show full text]
  • Medizinische Biotechnologie in Deutschland 2021
    BIOTECH-REPORT Medizinische Biotechnologie in Deutschland 2021 Biopharmazeutika: Wirtschaftsdaten und Therapiefortschritte durch Antikörper Die Boston Consulting Group (BCG) ist eine internationale Managementberatung und weltweit führend auf dem Gebiet der Unternehmensstrategie. BCG unterstützt Unternehmen aus allen Branchen und Regionen dabei, Wachstumschancen zu nutzen und ihr Geschäftsmodell an neue Gegebenheiten anzupassen. In partner schaftlicher Zusammenarbeit mit den Kunden entwickelt BCG individuelle Lösun gen. Gemeinsames Ziel ist es, nachhaltige Wettbewerbsvorteile zu schaffen, die Leistungsfähigkeit der Unternehmen zu steigern und das Geschäftsergebnisda uer haft zu verbessern. BCG wurde 1963 von Bruce D. Henderson gegründet und ist heute an mehr als 90 Standorten in über 50 Ländern vertreten. Das Unternehmen befindet sich im alleinigen Besitz seiner Geschäftsführer*innen. Weitere Informationen finden Sie auf unserer Internetseite www.bcg.de. Foto: DNA strands background: © Fotolia, Fotograf*in: Zffoto #104622650 Foto: Human antibody: © Fotolia, Fotografin: Tatiana Shepeleva #94084192 Der vfa ist der Wirtschaftsverband der forschenden Pharma-Unternehmen in Deutschland. Er vertritt die Interessen von 47 weltweit führenden forschenden Pharma-Unternehmen und über 100 Tochter- und Schwesterfirmen in der Gesundheits-, Forschungs- und Wirtschaftspolitik. Die Mitglieder des vfa repräsentieren mehr als zwei Drittel des gesamten deutschen Arzneimitt el- marktes und beschäftigen in Deutschland rund 80.000 Mitarbeiter*innen. Sie gewährleisten
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) FORMER DOCUMENT NUMBER: INN Working Document 05.179 © World Health Organization 2019 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Protein Complexes
    Tecniche immunochimiche ✓Principi generali: immunità umorale ✓Immunoglobuline: struttura, produzione anticorpi policlonali, monoclonali ✓Applicazioni: ▪ Immunoprecipitazione, immunodifusione, immunoelettroforesi, Co-IP, test di agglutinazione ▪ Dosaggi RIA, ELISA ▪ Immunoblotting: Western Blot ▪ Immunoistochimica (IHC) Microscopia fluorescenza, elettronica ▪ Citofluorimetria a flusso ▪ Impiego in terapia Determination of Ab affinity (Ka) by equilibrium dialysis. Semipermeable membrane A radioactively labeled ligand that is small to pass through (haptens, oligopeptides ) Plot of concentration of ligand in each compartment with time The difference in the two compartments Sensitivity of various immunoassays * * * * * * * * ** * * Determinanti antigenici/epitopi Complessi antigene- anticorpo Precipitation reactions in fluids yield a precipitiation curve ❖ Sensitivity ❖ Specificity Effect of Ab/Ag ratios on the formation of Ab-Ag precipitates Immunoprecipitation Immunoprecipitation (IP) is a technique to isolate a specific protein out of a solution using an antibody that binds to it. Antibody-protein complexes are removed from the solution with the addition of an insoluble form of an antibody binding protein, such as Protein A or Protein G Immunoprecipitation* *antibody conjugated to agarose or Magnetic Beads. Immunoprecipitation Immunoprecipitation assays detect the interaction of a target protein with other proteins or nucleic acids •Co-Immunoprecipitation (Co-IP) is a powerful method that is most widely used by researchers to analyze protein–protein interactions. This process provides a rapid and simple method to separate a specific protein from a sample containing thousands of different proteins, such as serum, cell lysate, homogenized tissue or conditioned media. Principle and method of co-immunoprecipitation (Co-IP) In Co-IP, complexes of two (or more) proteins are isolated using a procedure similar to the IP procedure. Co-IP is often used for the analysis of interactions of multiple proteins and their functions.
    [Show full text]
  • List Item Obiltoxaximab
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Obiltoxaximab SFL 100 mg/mL concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of concentrate contains 100 mg of obiltoxaximab. One vial of 6 mL contains 600 mg obiltoxaximab. Obiltoxaximab is produced in murine GS-NS0 myeloma cells by recombinant DNA technology. Excipient with known effect Each mL of concentrate contains 36 mg sorbitol. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for infusion (sterile concentrate). Obiltoxaximab SFL is a clear to opalescent, colourless to pale yellow to pale brownish-yellow solution that may contain few translucent-to-white proteinaceous particulates (which will be removed by in- line filtration) with a pH of 5.5 and an osmolality of 277 – 308 mOsm/kg. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Obiltoxaximab SFL is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to Bacillus anthracis (see section 5.1). Obiltoxaximab SFL is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.1). 4.2 Posology and method of administration Obiltoxaximab SFL should be given as soon as it is clinically indicated. Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of Obiltoxaximab SFL.
    [Show full text]
  • Development and Challenges to Monoclonal Antibodies for Passive Immunization
    Development and challenges to monoclonal antibodies for passive immunization Erin Sparrow 21 June 2017 1 | mAbs infectious diseases A brief history of serum derived passive immunization . Concept developed by von Behring & Kitasato in 1891 for serum therapy for tetanus. Nobel prize for von Behring in 1901 for diphtheria . Widely used in first half of 20th century: eg. , Measles, polio, pneumococcus, Hib, 1918 pandemic convalescent plasma . Use declined with vaccines and the discovery of antibiotics . But still used today for: RIG, DAT, TIG, BIG, HepA, HepB, HepC, VIG, VZIG…..etc. (Equine & Human) 2 | mAbs infectious diseases Opportunities for MAbs . Replacement of blood-derived Igs (supply issues) . Emerging infections . Pandemics . Function quicker than active vaccines . Where vaccines are not available . Antimicrobial resistance (eg. MSRA) . Opportunistic infections, immuno-supressed . Hospital acquired infections . Bio-defence (i.e anthrax) 3 | mAbs infectious diseases State of development: mAbs for infectious diseases . 5 Licensed: o RSV: Synagis (palivizumab) by MedImmune, since late 1990s o Anthrax: Abthrax (raxibacumab) by GSK & Anthim (obiltoxaximab) by Elusys therapeutics – both licensed under FDA animal rule in 2012 and 2016 o Rabies: RMAb (HuMAb17C7) by SII, licensed in India in 2016, not yet launched o Clostridium difficile (recurrent): Zinplava (Bezlotoxumab) by Merck, FDA approved in October 2016 . At least 38 in active clinical development for 13 diseases: . botulisum, C difficile, Ebola, hep B, hep C, Hendra virus, HSV, HIV, influenza, Pseudomona aeruginosa, rabies, RSV, Staph aureus . Numerous others in preclinical development… 4 | mAbs infectious diseases Challenges General: . Short duration of protection . Improving the mAb – longer ½ life, higher affinity . Route of administration (IV not ideal for LICs) Defining the purpose & endpoint & outcome measures .
    [Show full text]
  • Public Summary of Opinion on Orphan Designation Obiltoxaximab for the Treatment of Anthrax
    22 November 2018 EMA/532463/2018 Public summary of opinion on orphan designation Obiltoxaximab for the treatment of anthrax On 24 August 2018, orphan designation (EU/3/18/2065) was granted by the European Commission to SFL Regulatory Services GmbH, Austria, for obiltoxaximab for the treatment of anthrax. What is anthrax? Anthrax is a severe disease caused by infection with bacteria called Bacillus anthracis. The bacteria produce spores that are very resistant and can lay ‘dormant’ (inactive) until they find an organism where they can develop and multiply. Anthrax commonly affects animals such as sheep and cows, but can spread to humans when they are exposed to spores from infected animals or contaminated animal products. The most severe type of anthrax is inhalation anthrax, which occurs when a person has breathed in the bacteria’s spores. The first symptoms of inhalation anthrax are similar to a cold. Several days after the spores have been inhaled, they grow into new bacteria and start to release toxins, which cause internal bleeding, swelling and the death of tissue. Anthrax is a life-threatening disease because, if not treated early, it leads to the accumulation of fluid in the lungs, severe inflammation and bleeding of the tissues in the chest and haemorrhagic meningitis (inflammation and bleeding of the membranes that surround the brain and spine). What is the estimated number of patients affected by the condition? At the time of designation, anthrax affected less than 0.01 in 10,000 people in the European Union (EU). This was equivalent to a total of fewer than 500 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000.
    [Show full text]